Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Solid Tumor Clinical Trials

14 recruiting trials for Solid Tumor. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
14
Total Trials
14
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 1NCT05544240

Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors

SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that...

Sponsor: Williams Cancer FoundationEnrolling: 201 location
RECRUITINGPhase 1 / Phase 2NCT04787042

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab...

Sponsor: Simcha IL-18, Inc.Enrolling: 3166 locations
RECRUITINGPhase 1 / Phase 2NCT05803018

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including...

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.Enrolling: 381 location
RECRUITINGPhase 1 / Phase 2NCT06526819

SMP-3124LP in Adults With Advanced Solid Tumors

An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid...

Sponsor: Sumitomo Pharma America, Inc.Enrolling: 12010 locations
RECRUITINGPhase 1NCT06398418

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in...

The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein...

Sponsor: Rise Therapeutics LLCEnrolling: 331 location
RECRUITINGPhase 1 / Phase 2NCT02332668

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma...

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: *...

Sponsor: Merck Sharp & Dohme LLCEnrolling: 37017 locations
RECRUITINGPhase 1 / Phase 2NCT05144698

RAPA-201 Therapy of Solid Tumors

The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint...

Sponsor: Rapa Therapeutics LLCEnrolling: 371 location
RECRUITINGPhase 1 / Phase 2NCT05086692

A Beta-only IL-2 ImmunoTherapY Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor...

Sponsor: Medicenna Therapeutics, Inc.Enrolling: 11520 locations
RECRUITINGPhase 1 / Phase 2NCT06975293

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in...

Sponsor: STORM Therapeutics LTDEnrolling: 1883 locations
RECRUITINGPhase 1 / Phase 2NCT06810544

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part...

Sponsor: Tango Therapeutics, Inc.Enrolling: 19113 locations
RECRUITINGPhase 1 / Phase 2NCT06578624

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

The objective of this study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors. The study is comprised of 2...

Sponsor: Lamassu Bio IncEnrolling: 702 locations
RECRUITINGPhase 1NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid...

Sponsor: Bristol-Myers SquibbEnrolling: 33620 locations
RECRUITINGPhase 1NCT06452160

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515...

Sponsor: BridGene Biosciences Inc.Enrolling: 1031 location
RECRUITINGPhase 2NCT04970121

Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy

The study is to evaluate the efficacy and safety of duloxetine in Chinese solid tumor patients with taxanes-induced painful peripheral neuropathy. Duloxetine will be given to...

Sponsor: Yan Yang, MD, Ph.DEnrolling: 1001 location